Ballou WR[au] - Search Results

Year	Number of Results
1977	1
1984	1
1985	5
1986	3
1987	7
1988	6
1989	9
1990	5
1991	2
1992	2
1993	4
1994	3
1995	6
1996	7
1997	10
1998	8
1999	4
2000	1
2001	5
2002	3
2003	5
2004	4
2005	3
2006	4
2007	7
2008	9
2009	15
2010	7
2011	5
2012	2
2013	4
2014	3
2015	4
2016	5
2017	3
2019	1
2020	4
2021	1
2022	0

1

Malaria vaccines in development.

Ballou WR. Ballou WR. Expert Opin Emerg Drugs. 2005 Aug;10(3):489-503. doi: 10.1517/14728214.10.3.489. Expert Opin Emerg Drugs. 2005. PMID: 16083325 Review.

2

Plasmodium falciparum malaria vaccines in development.

Vekemans J, Ballou WR. Vekemans J, et al. Among authors: ballou wr. Expert Rev Vaccines. 2008 Mar;7(2):223-40. doi: 10.1586/14760584.7.2.223. Expert Rev Vaccines. 2008. PMID: 18324891 Review.

3

Ultra-low dose immunization and multi-component vaccination strategies enhance protection against malaria in mice.

Collins KA, Brod F, Snaith R, Ulaszewska M, Longley RJ, Salman AM, Gilbert SC, Spencer AJ, Franco D, Ballou WR, Hill AVS. Collins KA, et al. Among authors: ballou wr. Sci Rep. 2021 May 24;11(1):10792. doi: 10.1038/s41598-021-90290-8. Sci Rep. 2021. PMID: 34031479 Free PMC article.

4

Developing a human malaria sporozoite vaccine.

Young JF, Ballou WR, Hockmeyer WT. Young JF, et al. Among authors: ballou wr. Microb Pathog. 1987 Apr;2(4):237-40. doi: 10.1016/0882-4010(87)90121-5. Microb Pathog. 1987. PMID: 3333800 Review. No abstract available.

5

Malaria vaccine research.

Ballou WR, Diggs CL, Landry S, Hall BF. Ballou WR, et al. Science. 1994 Dec 16;266(5192):1792. doi: 10.1126/science.7864993. Science. 1994. PMID: 7864993

6

Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data.

Moorthy VS, Ballou WR. Moorthy VS, et al. Among authors: ballou wr. Malar J. 2009 Dec 30;8:312. doi: 10.1186/1475-2875-8-312. Malar J. 2009. PMID: 20042088 Free PMC article. Review.

7

The development of the RTS,S malaria vaccine candidate: challenges and lessons.

Ballou WR. Ballou WR. Parasite Immunol. 2009 Sep;31(9):492-500. doi: 10.1111/j.1365-3024.2009.01143.x. Parasite Immunol. 2009. PMID: 19691554 Review.

8

Development of a recombinant FimCH vaccine for urinary tract infections.

Langermann S, Ballou WR. Langermann S, et al. Among authors: ballou wr. Adv Exp Med Biol. 2003;539(Pt B):635-48. doi: 10.1007/978-1-4419-8889-8_41. Adv Exp Med Biol. 2003. PMID: 15176317 Review. No abstract available.

9

The Ratiometric Transcript Signature MX2/GPR183 Is Consistently Associated With RTS,S-Mediated Protection Against Controlled Human Malaria Infection.

Du Y, Thompson EG, Muller J, Valvo J, Braun J, Shankar S, van den Berg RA, Jongert E, Dover D, Sadoff J, Hendriks J, Gardner MJ, Ballou WR, Regules JA, van der Most R, Aderem A, Ockenhouse CF, Hill AV, Wille-Reece U, Zak DE. Du Y, et al. Among authors: ballou wr. Front Immunol. 2020 Apr 28;11:669. doi: 10.3389/fimmu.2020.00669. eCollection 2020. Front Immunol. 2020. PMID: 32411130 Free PMC article.

10

Non-CS pre-erythrocytic protective antigens.

Hollingdale MR, Aikawa M, Atkinson CT, Ballou WR, Chen GX, Li J, Meis JF, Sina B, Wright C, Zhu JD. Hollingdale MR, et al. Among authors: ballou wr. Immunol Lett. 1990 Aug;25(1-3):71-6. doi: 10.1016/0165-2478(90)90094-7. Immunol Lett. 1990. PMID: 2283163

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results